Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Europe Acute Care Syndromic Testing Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward. 
Market Dynamics
- Market Drivers
- Faster Results Acquired with Syndromic Tests
- Increasing Incidence of Infectious Diseases
- Overall Reduced Cost of Care due to Early Diagnosis with Syndromic Testing
- Reduced Severe Adverse Effects from Pathogens
- Market Challenges
- Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
- Lack of High-Complexity Testing Centres
- Market Opportunities
- Quick Access to Treatment and Reduced Use of Antibiotics
- High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years
Market Introduction
The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.
Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.
Market Segmentation
Segmentation 1: by End User
- Hospitals
- Clinical and Diagnostic Laboratories
- Research and Academic Institutions
- Other End Users
Segmentation 2: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence. Some of the prominent names in this market are:
- Biocartis N.V.
- bioMerieux S.A. (BioFire Diagnostics)
- DiaSorin S.p.A. (Luminex Corporation)
- Eurofins Scientific (Eurofins Viracor)
- QIAGEN N.V.
- QuantuMDx Group Ltd.
- Siemens Healthineers AG
Key Attributes
| Report Attribute | Details |
| No. of Pages | 110 |
| Forecast Period | 2023-2033 |
| Estimated Market Value (USD) in 2023 | $0.98 Billion |
| Forecasted Market Value (USD) by 2033 | $2.32 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Europe |
For more information about this report visit https://www.researchandmarkets.com/r/3ipnwi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
